Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Free Report) was the target of a large growth in short interest in July. As of July 31st, there was short interest totalling 19,880,000 shares, a growth of 7.8% from the July 15th total of 18,440,000 shares. Based on an average daily trading volume, of 1,220,000 shares, the short-interest ratio is presently 16.3 days.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on AVXL. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a research report on Thursday, August 1st. EF Hutton Acquisition Co. I raised Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd.
Read Our Latest Research Report on Anavex Life Sciences
Hedge Funds Weigh In On Anavex Life Sciences
Anavex Life Sciences Stock Performance
Shares of AVXL opened at $6.09 on Monday. The stock has a 50 day moving average price of $5.23 and a two-hundred day moving average price of $4.84. The firm has a market capitalization of $515.47 million, a P/E ratio of -12.18 and a beta of 0.63. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $10.45.
Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01. During the same period in the prior year, the business earned ($0.14) EPS. On average, equities analysts forecast that Anavex Life Sciences will post -0.55 earnings per share for the current year.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Read More
- Five stocks we like better than Anavex Life Sciences
- Conference Calls and Individual Investors
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Dividend Capture Strategy: What You Need to Know
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.